Selloff or Market Correction? Either Way, Here's What to Do NextSee Overvalued Stocks

Orbimed Advisors increased stake in LogicBio Therapeutics, Inc.

Published 10/05/2020, 07:13 PM
Updated 10/05/2020, 07:30 PM
© Reuters.  Orbimed Advisors increased stake in LogicBio Therapeutics, Inc.
ALPN
-
BMY
-
MRTX
-
EPIX
-
ALEC
-
TPTX
-
ETNB
-
TELA
-

On the 1st of October, Orbimed Advisors bought 1.5 million LogicBio Therapeutics, Inc. (LOGC) shares for $8.9 million at an average price of $6.00 per share. Shares of LogicBio Therapeutics, Inc. are up 3.71% since the transaction.

Orbimed Advisors's holding in LogicBio Therapeutics, Inc. increased to about 296 thousand shares with the purchase.

Orbimed Advisors first bought LogicBio Therapeutics, Inc. stock in the fourth quarter of 2018. Orbimed Advisors also owns Bristol-Myers Squibb Co (NYSE:BMY), Merck (MRK), Mirati Therapeutics Inc (NASDAQ:MRTX) and Turning Point Therapeutics, Inc. (NASDAQ:TPTX). LogicBio Therapeutics, Inc. is its number fifty three position by number of shares and market value among biotechnology & life sciences stocks.

Other investors who also added to their LogicBio Therapeutics, Inc. shares include California State Teachers Retirement System. Contrary to Orbimed Advisors, Victory Capital Management sold all their LOGC shares.

Orbimed Advisors has also recently reduced their share in Alector, Inc. (NASDAQ:ALEC). The total value of the shares sold is estimated at around $105 million.

In addition, Orbimed Advisors added to their share in Alpine Immune Sciences, Inc. (NASDAQ:ALPN), Adicet Bio, Inc. (ACET) and TELA Bio, Inc. (NASDAQ:TELA). The total value of the shares bought is estimated at around $79 million.

Orbimed Advisors also reduced their share in ESSA Pharma Inc . (NASDAQ:EPIX) and 89bio, Inc. (NASDAQ:ETNB). The total value of the shares sold is estimated at around $54 million.

Additionally, Orbimed Advisors established new holdings in Fusion Pharmaceuticals Inc. (FUSN). The total value of the shares bought is estimated at around $52 million.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.